Why has therapy development for dementia failed in the last two decades?

Alzheimer's and Dementia

Volumn 12, Issue 1, 2016, Pages 60-64

  Gauthier, Serge ^a   Albert, Marilyn ^b   Fox, Nick ^c   Goedert, Michel ^d   Kivipelto, Miia ^e   Mestre Ferrandiz, Jorge ^f   Middleton, Lefkos T ^g  

^a MCGILL UNIVERSITY   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Office of Health Economics   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's; Amyloid hypothesis; Attrition; Clinical trials; Dementia; Research development

Indexed keywords

BIOLOGICAL MARKER; NOOTROPIC AGENT; CHOLINESTERASE INHIBITOR; MEMANTINE;

AUTOSOMAL DOMINANT INHERITANCE; BABY BOOMER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; DISEASE CLASSIFICATION; DRUG INDUSTRY; DRUG RESEARCH; FRONTOTEMPORAL DEMENTIA; FUNDING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEWY BODY; PATIENT REFERRAL; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PHYSICAL INACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESEARCH DIAGNOSTIC CRITERIA; REVIEW; SIGNAL NOISE RATIO; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; TREATMENT FAILURE;

ALZHEIMER DISEASE; BIOMARKERS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DEMENTIA; DRUG DISCOVERY; HUMANS; MEMANTINE; TREATMENT FAILURE;

EID: 84953924384     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.12.003     Document Type: Short Survey

References (13)

1. Marsden G, Mestre-Ferrandiz J. 2015 Dementia: The R&D landscape. OHE Research Report. Available at: https://worlddmentiacouncil.wordpress.com. Accessed October 22, 2015.
2. G8 Dementia Summit Declaration. Available at: https://www.gov.uk/government/publications/g8-dementia-summit-agreeements. Accessed April 29, 2015.
3. L.S. Schneider, F. Mangialasche, N. Andreaden, H. Feldman, E. Giacobini, R. Jones, and et al. Clinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014 J Intern Med 275 2014 251 283
4. D. Calcoen, L. Elias, and Y. Xiaomeng What does it take to produce a breakthrough drug? Nat Rev Drug Discov 4 2015 161 162
5. A. Wimo, C. Ballard, C. Brayne, S. Gauthier, R. Handels, R.W. Jones, and et al. Health economic evaluation of treatments for Alzheimer's disease: Impact of new diagnostic criteria J Intern Med 275 2014 304 316
6. Alzheimer's Disease International. World Alzheimer Report 2015: The Global Impact of Dementia. Available at: http://www.alz.co.uk/research/world-report-2015. Accessed November 30, 2015.
7. Z. Khachaturian, M.M. Mesulam, A.S. Khachaturian, and R.C. Mohs The special topics of Alzheimer's & Dementia Alzheimers Dement 11 2015 1261 1264
8. M. Jitlal, I. Khan, S.M. Lee, and A. Hackshaw Stopping clinical trials early for futility: Retrospective analysis of several randomized clinical studies Br J Cancer 107 2012 910 917
9. M. Haas, V. Mantua, M. Haberkamp, L. Pani, M. Isaac, F. Butlen-Ducuing, and et al. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease Nat Rev Drug Discov 14 2015 221 222
10. S. Tomaszewski, S. Gauthier, A. Wimo, and P. Rosa-Neto Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer's disease: Socio-economic considerations modeled on treatments for tuberculosis, HIV/AIDS and breast cancer JPAD 2015 10.14283/jpad.2015.85 in press
11. S. Norton, F.E. Matthews, D.E. Barnes, K. Yaffe, and K.C. Brayne Potential for primary prevention of Alzheimer's disease: An analysis of population-based data Lancet Neurol 13 2014 788 794
12. F.E. Matthews, A. Arthur, L.E. Barnes, J. Bond, C. Jagger, L. Robinson, and et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: Results of the Cognitive Function and Ageing Study I and II Lancet 382 2013 1405 1412
13. T. Ngandu, J. Lehtisalo, A. Solomon, E. Levälahti, S. Ahtiluoto, R. Antikainen, and et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial Lancet 385 2015 2255 2263